RUSSELL WILKE

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain
    Qiping Feng
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 5:e15779. 2010
  2. pmc Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks
    Stephen D Turner
    Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 6:e19586. 2011
  3. pmc Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations
    Lili Ding
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    Hum Genomics 7:16. 2013
  4. pmc The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy
    R A Wilke
    Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 92:112-7. 2012
  5. pmc Mapping genes that predict treatment outcome in admixed populations
    T M Baye
    Division of Asthma Research, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
    Pharmacogenomics J 10:465-77. 2010
  6. pmc High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
    R A Wilke
    Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Pharmacogenomics J 11:162-73. 2011
  7. pmc The emerging role of electronic medical records in pharmacogenomics
    R A Wilke
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 89:379-86. 2011

Collaborators

Detail Information

Publications7

  1. pmc A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain
    Qiping Feng
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 5:e15779. 2010
    ..Mean HDL-C levels were 45±10, 47±10, and 48±9 mg/dL, respectively. The H3 CNR1 haplotype appears to exert a protective effect against development of obesity-related dyslipidemia...
  2. pmc Knowledge-driven multi-locus analysis reveals gene-gene interactions influencing HDL cholesterol level in two independent EMR-linked biobanks
    Stephen D Turner
    Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
    PLoS ONE 6:e19586. 2011
    ..These results demonstrate that gene-gene interactions modulate complex human traits, including HDL cholesterol...
  3. pmc Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations
    Lili Ding
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
    Hum Genomics 7:16. 2013
    ..We performed genome-wide association studies on 859,790 SNPs genotyped in 527 affected offspring trios of European, African, and Hispanic ancestry using publically available asthma database in the Genotypes and Phenotypes database...
  4. pmc The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy
    R A Wilke
    Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 92:112-7. 2012
    ..This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly...
  5. pmc Mapping genes that predict treatment outcome in admixed populations
    T M Baye
    Division of Asthma Research, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
    Pharmacogenomics J 10:465-77. 2010
    ....
  6. pmc High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
    R A Wilke
    Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Pharmacogenomics J 11:162-73. 2011
    ..As these biobanks combine resources, the clinical community is in a position to characterize lipid-related treatment outcome on an unprecedented scale...
  7. pmc The emerging role of electronic medical records in pharmacogenomics
    R A Wilke
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 89:379-86. 2011
    ..This review explores each of these translational mechanisms within a historical framework...

Research Grants3

  1. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    RUSSELL WILKE; Fiscal Year: 2009
    ..In the future, individual patients with variation in these genes may benefit from targeted behavioral and/or pharmacological interventions designed to improve their health. ..
  2. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2010
    ..In the future, individual patients with variation in these genes may benefit from targeted behavioral and/or pharmacological interventions designed to improve their health. ..
  3. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2009
    ..In the future, individual patients with variation in these genes may benefit from targeted behavioral and/or pharmacological interventions designed to improve their health. ..